Intravenous or Subcutaneous Atezolizumab for Bladder Cancer After Surgery
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer.
The U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA (ctDNA) after cystectomy, signaling the presence of molecular residual disease (MRD).
The FDA also approved Signatera CDx, a companion diagnostic device to identify therapy-eligible patients with MRD through ctDNA detection.
Atezolizumab is an immune checkpoint inhibitor that blocks the binding between the protein PD-L1 (present on cancer and other cells) and the PD-1 and PD-2 receptors (expressed on T cells). Interaction of PD-L1 with its receptors sends an inhibitory signal that prevents activation of T cells. Therefore, atezolizumab treatment reverses the inhibitory signal and restores the ability of T cells to recognize and kill cancer cells. Atezolizumab (without hyaluronidase-tqjs) is administered as an intravenous infusion.
Hyaluronidase-tqjs is an enzyme that partially breaks down the extracellular matrix and facilitates absorption of atezolizumab, which allows for delivery of atezolizumab and hyaluronidase-tqjs as a subcutaneous injection.
MRD indicates the persistence of microscopic amounts of cancer in the body after surgery. These trace amounts are not detectable via traditional imaging methods but can be revealed through molecular assays that detect fragments of genetic material shed by the cancer cells into the bloodstream, such as ctDNA.
Treatment guided by the presence of MRD can help ensure that only patients with residual cancer receive the therapy, thereby sparing ctDNA-negative patients from potential immunotherapy-related toxicity.
This is the first FDA approval for a solid tumor to include a requirement for ctDNA positivity.
The approval was based on results from IMvigor011, a multicenter, randomized, double-blind, placebo-controlled phase III trial that evaluated the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in 250 patients with MIBC. Patients had undergone a surgical procedure to remove the bladder, surrounding lymph nodes, and nearby organs (radical cystectomy) and had ctDNA detectable in their blood during the subsequent 12 months, starting at least six weeks after surgery, which indicates high risk for disease recurrence.
Patients were randomly assigned (2:1) to receive either 1,680 mg of atezolizumab or placebo intravenously every four weeks for up to 12 cycles or one year (whichever occurred first). Treatment was discontinued early in case of disease recurrence or unacceptable toxicity.
Investigators observed a statistically significant improvement in disease-free survival (DFS) in patients who received atezolizumab compared to placebo, with a median DFS of 9.9 months for the atezolizumab arm and 4.8 months for the placebo arm. This corresponded to a 36% reduction in the risk of cancer recurrence or death in patients treated with atezolizumab. Median overall survival was 32.8 months in the atezolizumab arm and 21.1 months in the placebo arm, indicating that atezolizumab treatment led to a 41% decrease in the risk of death by any cause compared with placebo.
The recommended dose of intravenous atezolizumab is 840 mg every two weeks; 1,200 mg every three weeks; or 1,680 mg every four weeks for up to one year. The prescribing information recommends stopping treatment early in case of disease recurrence or unacceptable toxicity. The recommended dose of atezolizumab and hyaluronidase-tqjs administered subcutaneously is 1,875 mg of atezolizumab and 30,000 units of hyaluronidase-tqjs every three weeks for up to one year, unless disease recurrence or unacceptable toxicity occurs. In patients who have a negative ctDNA test, repeated testing should continue until a positive result or completion of the recommended 12-month testing window.
Bladder cancer is a type of cancer that originates in the lining of the bladder. When bladder cancer advances to the muscle tissue that surrounds the bladder’s lining, it is categorized as MIBC. The National Cancer Institute estimated that 84,530 individuals would be diagnosed with bladder cancer, and 17,870 patients would die of the disease in the United States in 2026.
The FDA rendered its decision on May 15, 2026. Check this resource for updated information on all therapeutics regulated by the FDA.